A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
A phase 2 trial of Acalabrutinib, Venetoclax, Rituximab in mantle cell lymphoma, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05951959 by AstraZeneca, with 108 participants enrolled, started 2023-12-13 and due to reach its primary completion in 2028-10-31. Interventions recorded: Acalabrutinib, Venetoclax, Rituximab. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Shares Acalabrutinib, Mantle cell lymphoma, Rituximab, AstraZeneca.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Acalabrutinib, Mantle cell lymphoma, Rituximab, AstraZeneca.
- TrialAn Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialStudy of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Acalabrutinib, Venetoclax, AstraZeneca.
- TrialStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Acalabrutinib, Rituximab, AstraZeneca.
- TrialStudy of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Shares Acalabrutinib, Rituximab, AstraZeneca.